Overview

A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors

Status:
Not yet recruiting

Trial end date:
2026-12-30

Target enrollment:

Participant gender:

Summary

This is A Phase Ib/II Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients with Advanced Solid Tumors

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Shanghai Antengene Corporation Limited